Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12693661 | 0.83 | LMNA (0.35) | LMNAEIF4A3TRPV1TRPA1CHRM1 | |
| SCHEMBL18310663 | 0.82 | EIF4A3 (0.35) | LMNAEIF4A3TRPV1TRPA1CHRM1 | |
| SCHEMBL24319896 | 0.81 | LMNA (0.38) | LMNAEIF4A3TRPV1TRPA1CHRM1 | |
| SCHEMBL19756648 | 0.81 | PDE2A (0.34) | PDE2AALDH1A1 | |
| SCHEMBL21567158 | 0.80 | CYP3A4 (0.38) | LMNAEIF4A3TRPV1TRPA1CHRM1 | |
| SCHEMBL13038361 | 0.79 | LMNA (0.39) | LMNATRPV1TRPA1CHRM1SLC6A2 | |
| SCHEMBL12992602 | 0.77 | LMNA (0.38) | LMNATRPV1TRPA1CHRM1SLC6A2 | |
| SCHEMBL15247293 | 0.77 | LMNA (0.40) | LMNAEIF4A3TRPV1TRPA1CHRM1 | |
| SCHEMBL12599604 | 0.77 | LMNA (0.35) | LMNAEIF4A3TRPV1TRPA1CHRM1 | |
| SCHEMBL16982944 | 0.76 | ALDH1A1 (0.39) | HTR2BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230017045-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | DOW AGROSCIENCES LLC (US) | 2023-01-19 | — | — | US | disclosed |
| US-10815197-B2 | N-sulfonyl benzamides as voltage-gated sodium channel inhibitors | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2020-10-27 | — | — | US | disclosed |
| WO-2020198266-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-10-01 | — | — | WO | disclosed |
| US-20190023654-A1 | N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230017045-A1 | PYRIDINE AND PYRIMIDINE CARBOXYLATE HERBICIDES AND METHODS OF USE THEREOF | PDXK, DPYD, DDT | LMNA 4716/4885EIF4A3 2102/4885TRPV1 3002/4885 |
| US-10815197-B2 | N-sulfonyl benzamides as voltage-gated sodium channel inhibitors | SCN11A, SCN8A, NHERF1 | LMNA 2491/4885EIF4A3 3668/4885TRPV1 18/4885 |
| US-20190023654-A1 | N-SULFONYL BENZAMIDE DERIVATIVE WITH HETEROCYCLIC SUBSTITUENT, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | SLC5A11, SLC6A11, SLC5A1 | LMNA 2737/4885EIF4A3 3486/4885TRPV1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.